Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not Allowed)
ID: 351096Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351096

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-017.html
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Nov 21, 2023 12:00 AM
  4. 4
    Due Feb 23, 2026 12:00 AM
Description

The National Institutes of Health (NIH) has posted a grant opportunity titled "Miniaturization and Automation of Tissue Chip Systems (MATChS)" under the category of Health. This opportunity is a Cooperative Agreement and does not require cost sharing or matching. The grant is open to Small Businesses.

The purpose of this grant is to support the development of MATChS through the SBIR cooperative agreement mechanisms. The goal is to fund research and development projects that focus on creating tools and turnkey technologies for higher throughput automated measures with on-line sensing. The aim is to reduce manual handling and enable rapid acquisition and analysis of data. The ultimate outcome of the funded projects will be the availability of miniaturized automated tissue chip platforms. These platforms will be used in drug development and various biomedical research laboratories.

As a cooperative agreement, small business concerns (SBCs) are expected to develop milestones and benchmarks. They will work closely with NIH staff to ensure progress in the project's aims, which include the development of an automated system and demonstrable pathways to commercialization.

The closing date for this grant opportunity is February 23, 2026. For more information and to apply, please visit the following link: Miniaturization and Automation of Tissue Chip Systems (MATChS) Grant Opportunity. If you have any inquiries, please contact NIH Grants Information at grantsinfo@nih.gov.

Point(s) of Contact
grantsinfo@nih.gov
Files
Title
Posted
RFA-TR-23-017-Full-Announcement.html
4/10/2024
Similar Opportunities
Miniaturization and Automation of Tissue Chip Systems (MATChS) (UT1/UT2 - Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Miniaturization and Automation of Tissue Chip Systems (MATChS) (UT1/UT2 - Clinical Trial Not Allowed)". This opportunity falls under the category of Health and is a Cooperative Agreement funding instrument type. Small businesses are eligible to apply for this grant. The purpose of this grant is to support the development of MATChS using the Small Business Technology Transfer (STTR) cooperative agreement mechanisms. The goal is to fund research and development projects that focus on the creation of tools and turnkey technologies for higher throughput automated measures with on-line sensing. The aim is to reduce manual handling and enable rapid acquisition and analysis of data. The ultimate outcome of the funded projects will be the availability of miniaturized automated tissue chip platforms. These platforms will be used in drug development and various biomedical research laboratories. As a cooperative agreement, small business concerns (SBCs) are expected to develop milestones and benchmarks. They will work closely with NIH staff to make progress in the project's aims, which include the development of an automated system and demonstrable pathways to commercialization. The grant opportunity does not require cost sharing or matching. The deadline for applications is February 23, 2026, and the archive date is March 31, 2026. For more information and to apply, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-018.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-018.html). Any inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R43/R44 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models" under the category of Health. This grant is specifically for Small Businesses and does not require cost sharing or matching. The purpose of this grant is to support the development of innovative tools and devices that improve the handling of laboratory animals, facilitate the management of animal facilities, and enhance experiments that utilize animal models. The goal is to directly benefit the welfare of research animals and improve the infrastructure and environmental conditions of animal facilities involved in biomedical and bio-behavioral research. Small Business Innovation Research (SBIR) projects are encouraged to apply. The deadline for applications is September 5, 2024. For more information and to apply, please visit the following link: [http://grants.nih.gov/grants/guide/pa-files/PAR-21-225.html](http://grants.nih.gov/grants/guide/pa-files/PAR-21-225.html). For any further inquiries, please contact the NIH OER Webmaster at grantsinfo@nih.gov.
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)". This grant is part of the Health category and falls under the Grant funding instrument type. The grant does not require any cost sharing or matching requirement. The purpose of this grant is to provide additional funding to small business concerns (SBCs) that have previously received SBIR or STTR Phase II awards from any Federal agency. The goal is to support the next stage of development for cancer-relevant projects and facilitate their transition to the commercialization stage. The NIH expects this grant to promote partnerships between SBIR or STTR Phase II awardees and third-party investors or strategic partners, in order to accelerate the capital-intensive steps required for commercializing new products and services. Applicants are required to submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. The level of independent third-party funding should be equal to or greater than the funds being requested from the NCI throughout the project period. Proposed projects may address preclinical and/or clinical stages of technology development, and while clinical trials may be proposed, they are not mandatory. Small businesses are eligible to apply for this grant opportunity. However, non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. The close date for this grant opportunity is August 21, 2024, and the last updated date is April 23, 2024. For more information and to apply, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-022.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-022.html). If there are any inquiries, they can be directed to NIH Grants Information at grantsinfo@nih.gov.
SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed)". This grant aims to support small business concerns (SBCs) in transitioning their previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage. The grant provides additional support for technical assistance and later stage research and development (R&D) that is not typically covered by Phase II or Phase IIB grants or contracts. The services/items being procured through this grant may include independent replication of key studies, Investigational New Drug (IND)-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. It is important to note that clinical trials are not accepted under this grant. Small businesses are eligible to apply for this grant opportunity. Non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations are not eligible to apply. However, foreign components, as defined in the NIH Grants Policy Statement, may be allowed. The close date for this grant opportunity is April 5, 2025. For more information and to apply, interested applicants can visit the following website: [SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development Grant](http://grants.nih.gov/grants/guide/pa-files/PAR-23-219.html). For any inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed
Active
National Institutes of Health
The National Institutes of Health is offering a federal grant opportunity titled "Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed". This grant aims to support the development of novel extracellular vesicle-based therapeutic platforms for use in regenerative medicine. Extracellular vesicles (EVs) have shown potential for targeted tissue and organ repair, making them suitable for applications in therapeutics. The funding opportunity focuses on platform-oriented technology development associated with the production, manufacturing, and use of EVs as therapeutics in regenerative medicine. Small businesses are eligible to apply, while non-U.S. entities and non-U.S. components of U.S. organizations are not eligible. The grant does not require cost sharing or matching. The maximum award ceiling is $295,924. The deadline for application submission is June 6, 2025. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/pa-files/PAR-23-268.html](http://grants.nih.gov/grants/guide/pa-files/PAR-23-268.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.